维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="Verzoni"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?显示文摘	Emilio Bajetta Laura Catena Giuseppe Procopio Sara Dosso Ettore Bichisao Leonardo Ferrari Antonia Martinetti Marco Platania Elena Verzoni Barbara Formisano Roberto Bajetta	2007	Cancer Chemotherapy and Pharmacology2007，，：	2
2	Renal cell cancer andsorafenib : skin toxicity and treatment outcome 显示文摘	Bajetta E Procopio G Verzoni E	2007	Tumori2007，93，2：	1
3	Time from ncphrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiv- ing targeted therapies : overall results from a large cohort of patients 显示文摘	Procopio G Testa I Verzoni E	2014	Oncology2014，88，3：	1
4	Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma显示文摘	Procopio G Verzoni E Gevorgyan A	2007	Oncol2007，，：	1
5	Large open-label,noncompara- tive ,clinical experience trial of the multi-targeted kinase inhibitor so- rafenib in European patients with advanced RCC显示文摘	Beck JG Proeopio E Verzoni S	2008	J Clin Oncol2008，26，16：	1
6	Feasibility studyof biweekly capecitabine,Oxaliplatin and irinotecan in patientswith untreated advanced gastric cancer显示文摘	BAJETTA E VERZONI E FERRARIO E	2009	Tumori2009，95，1：	1
7	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib显示文摘	Grassi P Verzoni E Porcu L	2015	Adv Urol2015，7，2：	1
8	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases 显示文摘	Proeopio G Verzoni E Iaeovelli R	2012	Clin Exp Nephrol2012，16，3：	1
9	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies显示文摘	Procopio G Verzoni E Iacovelli R		0，，8：	1
10	Renal cell cancer and sorafenib: skin toxicity and treatment outcome显示文摘	Bajetta E Procopio G Verzoni E	2007	Tumori2007，93，2：	1
11	Renal cell cancer and sorafenib , skin toxicity and treatment outcome显示文摘	Bajetta E Procopio G Verzoni E	2007	Tumori2007，93，2：	1
12	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases显示文摘	Procopio G Verzoni E Iacovelli R	2012	Clin Exp Nephrol2012，16，3：	1
13	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases显示文摘	Procopio G Verzoni E Iacovelli R		0，，03：	1
14	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma?Efficacy data from a retrospective analysis of 7 cases显示文摘	Procopio G Verzoni E lacovelli R	2012	Clin Exp Nephrol2012，16，3：	1
15	Renal cell cancer and sorafenib: skin toxicity and treatment outcome 显示文摘	Bajetta E Procopio G Verzoni E	2007	Tumori2007，93，2：	1
16	Targeted treatments in advancedrenal cell carcinoma:focus on axitinib 显示文摘	Verzoni E Grassi P Testa I	2014	PharmgenomicsPers Med2014，27，7：	1
17	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib显示文摘	Grassi P Verzoni E Porcu L	2015	Ther Adv Urol2015，7，2：	1
18	Is there a role for targeted therapies in the collecting ducts of bellini carcino- ma? Efficacy data from a retrospective analysis of 7 cases显示文摘	Giuseppe Procopio Elena Verzoni Roberto lacovelli	2012	Clin Exp Nephrol2012，16，3：	1
19	Renal cell cancerand sorafenib: skin toxicity and treatment outcome 显示文摘	Bajetta E Procop io G Verzoni E	2007	Tumori2007，93，2：	1
20	A large open-lable,non-comparative,phase Ⅲ study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma显示文摘	Beck J Verzoni E Negrier S	2008	European Urology Supplements2008，7，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示